For Immediate Release

Organization Profile: 
Contact: 

Phone: 202-588-1000

Gilead Must Relinquish Monopoly on Potential Coronavirus Treatment

51 Groups Warn Gilead Against Profiteering Off the Pandemic.

WASHINGTON - Gilead Sciences must immediately renounce its claim to a lucrative orphan drug designation for remdesivir – one of a few medicines being explored as a possible treatment for the coronavirus. That’s what Public Citizen and 50 groups said in a letter sent today to Daniel O’Day, chairman and CEO of the pharmaceutical giant.

The orphan drug designation, which the U.S. Food and Drug Administration granted Gilead on Monday, will provide Gilead with seven years of marketing exclusivity – helping the company to shut out competitors and charge high monopoly prices. Gilead received this designation only by rushing to file its application while there were fewer than 200,000 known COVID-19 cases in the U.S. That is the population cap for eligibility as an orphan drug – one designed to treat rare diseases. Due to a lack of widely available testing, the number of cases likely already has surpassed that mark.

SCROLL TO CONTINUE WITH CONTENT

Never Miss a Beat.

Get our best delivered to your inbox.

“This is an unconscionable abuse of a program designed to incentivize research and development of treatments for rare diseases,” the letter reads. “COVID-19 is anything but a rare disease. Calling COVID-19 a rare disease mocks people’s suffering and exploits a loophole in the law to profiteer off a deadly pandemic. Making the claim to special orphan status even more outrageous is the fact that the public already has largely paid for remdesivir’s development through at least $60 million in grants and innumerable contributions from federal scientists. America, and the world, has the right to expect better from Gilead.”

Gilead must reverse course and renounce its claim to orphan drug designation privileges for remdesivir, the groups insist.

###

Our pandemic coverage is free to all. As is all of our reporting.

No paywalls. No advertising. No corporate sponsors. Since the coronavirus pandemic broke out, traffic to the Common Dreams website has gone through the roof— at times overwhelming and crashing our servers. Common Dreams is a news outlet for everyone and that’s why we have never made our readers pay for the news and never will. But if you can, please support our essential reporting today. Without Your Support We Won't Exist.

Please select a donation method:



Public Citizen is a national, nonprofit consumer advocacy organization founded in 1971 to represent consumer interests in Congress, the executive branch and the courts.

Share This Article